glp-1 and dpp-4 inhibitors DPP4 vs Agonists | June 2021 | Clinical Corner Clinical Use of DPP-4 Inhibitors

If youre worried, dont wait to seek advice taking care of yourself should always be a priority

A new review explores how GLP-1 receptor agonists may blunt alcohol and drug reward signals, opening a promising but still unproven path toward repurposed treatments for addiction

When you superimpose patients with obesity but with low muscle mass and strength, they are at greater risk of adverse outcomes, Batsis says

Common Gastrointestinal Adverse Effects and Mitigation Strategies The introduction of resistant starch into the diet commonly produces gastrointestinal symptoms as the gut microbiota adapts to increased substrate availability

Completely normal

Programs may include Semaglutide and Tirzepatide